Bicara Therapeutics Inc. Common Stock (BCAX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bicara Therapeutics Inc. Common Stock (BCAX) has a cash flow conversion efficiency ratio of -0.094x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-44.21 Million) by net assets ($468.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BCAX market cap for the company's overall valuation and market capitalisation.
Bicara Therapeutics Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Bicara Therapeutics Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bicara Therapeutics Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bicara Therapeutics Inc. Common Stock ranked by their cash flow conversion efficiency. See Bicara Therapeutics Inc. Common Stock cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sunshine Global Circuits Co Ltd Class A
SHE:300739
|
0.049x |
|
Tabcorp Holdings Ltd
AU:TAH
|
0.075x |
|
Fengzhushou Co. Ltd. A
SHE:301382
|
N/A |
|
Shanghai Highly Group Co Ltd A
SHG:600619
|
0.019x |
|
Aerospace Nanhu Electronic Information Technology Co. Ltd. A
SHG:688552
|
N/A |
|
YGSOFT Inc
SHE:002063
|
0.011x |
|
Proeduca Altus S.A.
MC:PRO
|
0.577x |
|
Americas Silver Corp
TO:USA
|
-0.213x |
Annual Cash Flow Conversion Efficiency for Bicara Therapeutics Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Bicara Therapeutics Inc. Common Stock from 2022 to 2025. View Bicara Therapeutics Inc. Common Stock share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $401.45 Million | $-106.83 Million | -0.266x | -75.11% |
| 2024-12-31 | $491.88 Million | $-74.75 Million | -0.152x | +27.22% |
| 2023-12-31 | $218.51 Million | $-45.63 Million | -0.209x | -111.25% |
| 2022-12-31 | $-17.28 Million | $-32.08 Million | 1.856x | -- |
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was … Read more